Haleon Q1 Growth Misses Estimates on Weak Flu Season

Q1 Growth Falls Short of Expectations

Haleon reported first-quarter organic sales growth of 2.2%, falling slightly below the consensus estimate of 2.4%. The consumer health giant attributed the miss to a significant 1.3 percentage point headwind from a weak cold and flu season, which followed a similar impact in the previous quarter.

Overall Performance and Regional Breakdown

The company's performance was characterized by a 0.2% decline in volume, offset by a 2.4% increase in pricing. Growth in North America was modest at 1.0%, while emerging markets slowed to 4.3%. Key product categories showed mixed results; Oral Health, featuring Sensodyne, saw double-digit growth, whereas digestive health and supplements underperformed. Respiratory health met estimates, balancing a strong allergy season against poor cold and flu product sales.

Maintained Full-Year Outlook

Despite the challenging quarter, Haleon reaffirmed its full-year guidance. The company continues to project organic sales growth between 3% and 5% and expects operating margin expansion. This signals confidence in its strategy to navigate market headwinds and achieve its annual targets, with an anticipated operating margin approaching 24%.

Stable Forecast Amidst Headwinds

Haleon's decision to maintain its full-year forecast suggests that the impact of the weak flu season is considered a temporary setback. The market will be closely watching the company's performance in subsequent quarters to see if growth can accelerate to meet its annual ambition of 4% growth, excluding the cold and flu category.

FAQ

Q: Why did Haleon miss its Q1 sales estimates?
A: The company's sales were negatively impacted by a weaker-than-expected cold and flu season, which reduced demand for related products.

Q: What was Haleon's organic sales growth in the first quarter?
A: Haleon reported an organic sales growth of 2.2% for the first quarter.

Q: Did Haleon change its financial forecast for the year?
A: No, Haleon maintained its full-year guidance for organic sales growth of 3% to 5% and an expansion in operating margin.

Source: Investing.com